Yumanity Therapeutics, Inc.

NasdaqCM:YMTX Stock Report

Market Cap: US$143.6m

Yumanity Therapeutics Balance Sheet Health

Financial Health criteria checks 6/6

Yumanity Therapeutics has a total shareholder equity of $5.5M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $9.6M and $4.1M respectively.

Key information


Debt to equity ratio



Interest coverage ration/a
Total liabilitiesUS$4.10m
Total assetsUS$9.58m

Recent financial health updates

No updates

Recent updates

Financial Position Analysis

Short Term Liabilities: YMTX's short term assets ($9.1M) exceed its short term liabilities ($4.1M).

Long Term Liabilities: YMTX has no long term liabilities.

Debt to Equity History and Analysis

Debt Level: YMTX is debt free.

Reducing Debt: YMTX had no debt 5 years ago.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: YMTX has sufficient cash runway for 4 months based on last reported free cash flow, but has since raised additional capital.

Forecast Cash Runway: YMTX is forecast to have sufficient cash runway for 3 months based on free cash flow estimates, but has since raised additional capital.

Discover healthy companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.